VIVO CAPITAL, LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

72 -1.37%

of those in investment advisory functions:

43 -10.42%

Registration:

SEC, Approved, 6/18/2014

Other registrations (2)
AUM:

5,809,839,447 7.22%

of that, discretionary:

5,809,839,447 7.22%

Private Fund GAV:

6,018,460,663 -10.42%

Avg Account Size:

387,322,630 7.22%

SMA’s:

NO

Private Funds:

15

Contact Info

650 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
6B 6B 5B 4B 3B 2B 924M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Recent News

Vivo Capital, LLC Buys ALX Oncology Holdings Inc, Bolt Biotherapeutics Inc, Bolt ...
08/24/2021

Related Stocks: MRUS, ALXO, BOLT, BOLT, TERN, IMPL, VALN, AKRO, CGEM, KALA, ATRC, CNST, IGMS,

gurufocus.com

Seattle biotech firm Impel NeuroPharma files for $75M IPO
04/05/2021

Seattle-based biotech company Impel NeuroPharma is set to go public. The company, which develops drugs for central nervous system disorders such as migraines and

MSN

VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled | Morningstar
03/31/2021

Mutual Funds Stocks ETFs Bonds Best Investments Portfolio Markets Investing Learn Start Investing Investing Classroom Investing Glossary Help Center Plan Tax Planning Personal Finance ...

Morningstar

VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled
03/31/2021

SHANGHAI, March 31, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced on March 30 that it had successfully ...

prnewswire.com

Fortis Therapeutics Raises $40M in Series A Funding
03/29/2021

Fortis Therapeutics, Inc., a San Diego, CA-based immuno-oncology biotech company, closed a $40m Series A financing

finsmes.com

Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myel
03/29/2021

Fortis Therapeutics, Inc., an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing. Participating in this financing are existing investors,

us.acrofan.com


Private Funds Structure

Fund Type Count GAV
Private Equity Fund 5 $3,995,733,118
Venture Capital Fund 7 $781,739,139
Other Private Fund 3 $1,240,988,406

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
CLOSED LOOP PARTNERS, LLC - - 121.4m - - 39.9m 144.3m 345.6m 492.3m 16
ATHOS PRIVATE WEALTH LLC - - 8.2m - - 31.8m 4.3m 76.2m 139.1m 21
WESTRIVER MANAGEMENT, LLC - - 240.8m - - 620.7m 134.0m 1.6b 995.5m 41
FOUNDERS CIRCLE CAPITAL, LLC - - 222.1m - - 800.1m - 1.8b 1.0b 22
BIP CAPITAL - - 527.3m - - 373.0m - 1.3b 1.0b 43
HOF CAPITAL - - 320.9m - - 667.0m - 1.7b 1.1b 61
CARBON DIRECT CAPITAL MANAGEMENT LLC - - 201.5m - - 490.7m - 1.2b 692.2m 5
INNOVIUS CAPITAL MANAGEMENT, LLC - - 148.4m - - 217.1m - 582.6m 365.5m 6
BIP CAPITAL MANAGEMENT SERVICES, LLC - - 155.6m - - 180.0m - 515.7m 335.7m 18
IMPACT ENGINE - - 54.1m - - 46.0m - 146.1m 168.6m 7

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
834203309 Soleno Therapeutics Inc $298,527,521 28.00% -17.00% -13.00%
374163103 Geron Corp $115,435,238 11.00% 28.00% 0.00%
413197104 Harmony Biosciences Holdings Inc $78,630,472 7.00% -10.00% 0.00%
P8696W104 Sinovac Biotech Ltd. $76,346,000 7.00% 0.00% 0.00%
925050106 Verona Pharma PLC $51,329,501 5.00% -12.00% -2.00%
05337M104 Avadel Pharmaceuticals PLC $55,847,712 5.00% -17.00% 0.00%
26818M108 Dyne Therapeutics Inc $57,703,949 5.00% 24.00% 0.00%
880881107 Terns Pharmaceuticals Inc $42,106,176 4.00% -4.00% -7.00%
92790C104 Viridian Therapeutics Inc $21,833,473 2.00% -26.00% 0.00%
82686Q101 Silence Therapeutics PLC $21,003,626 2.00% -12.00% 0.00%

Brochure Summary

Overview

A. Vivo Capital LLC (“Vivo” or the “Firm”), formerly known as Vivo Ventures, LLC and BioAsia, LLC, is a California limited liability company. Vivo has been in business since 1996 and has been a registered investment adviser since 2014. Vivo serves as an investment adviser to pooled investment vehicles (each, a “Fund” or a “Client” and collectively the “Funds” or “Clients”)1. Vivo’s Funds are reported on Form ADV 1A. An affiliate of Vivo serves as the general partner (or similar managing body) of each Fund. Vivo currently has over 40 investment professionals based both in the U.S. and in Greater China. Vivo’s principal owner is Dr. Frank Kung. B. Vivo is a global healthcare investment firm that focuses on finding and building value in healthcare companies. Vivo invests in both public and private healthcare companies. Vivo is affiliated with entities that serve as the general partners (or similar capacity with regards to entities formed in other jurisdictions) to each of the Funds (each, a “General Partner” and, collectively, the “General Partners”) and each of the Funds is controlled by its respective General Partner. The following is a list of each of the General Partners of the Funds: General Partners:
• Vivo Ventures VII, LLC

• Vivo Ventures Cayman VII (GP), L.P.
• Vivo Capital VIII, LLC
• Vivo Panda, LLC
• Vivo Opportunity, LLC
• Vivo Asia Opportunity, LLC
• Vivo Capital IX, LLC
• Vivo Capital IX (Cayman), LLC
• Vivo Innovation II, LLC
• Vivo Capital X, LLC C. The investment focus and risks of the Funds are more particularly described in each Fund’s offering and governing documents. These guidelines may provide for limits on the size, concentration, geography, type of security and/or terms of the Fund’s investments. The Firm does not tailor its advisory services to individual investors in its Funds. D. The Firm does not participate in wrap fee programs. 1 “Fund” or “Client” means a private investment fund to which Vivo provides investment advice and/or invests on a discretionary basis. The individuals and other persons that invest in the Vivo private investment funds are generally referred to herein as “investors.” Unless otherwise expressly stated herein, the terms “Fund” and “Client” do not include “investors.” E. As of December 31, 2023, Vivo managed $5,809,839,447 in client assets on a discretionary basis. Vivo does not manage any client assets on a non-discretionary basis.